The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: GlaxoWellcome
Approval Status: Approved February 1998
Treatment for: acute migraine
General Information
Amerge (naratriptan hydrochloride) Tablets have been approved for the treatment of acute migraine. Amerge is a selective 5-HT agonist designed specifically to treat migraine attacks. In clinical trials, 60-66% of patients with moderate to severe headache responded to Amerge 2.5 mg within four hours. Of the patients who had relief with the initial dose, 72-81% did not have recurrence of headache within 24 hours.
Amerge is indicated for the acute treatment of migraine attacks with or without aura in adults. Amerge is not intended to prevent or reduce the number of migraine attacks nor is it for use in the treatment of cluster headache, or management of basilar or hemiplegic migraine.
Side Effects
The only reported side effect with a greater than 2% incidence was nausea 5%.
